Trump cuts to science advisory boards have long-lasting consequences, researchers say

The Trump administration has dissolved more than 100 federal science and healthcare advisory committees in 2025, according to analysis by research organizations and advocacy groups. The widespread terminations affect panels established under the Federal Advisory Committee Act, removing outside expert guidance on public health priorities, biomedical research, climate science, and space exploration.

According to the advocacy group Public Citizen, more than 25 percent of federal healthcare advisory panels were shut down by March. The Union of Concerned Scientists separately tracked 150 science-related advisory committees terminated across federal agencies this year. The boards, composed primarily of volunteer experts, have historically provided independent recommendations on issues ranging from vaccine schedules and cancer screenings to hospital infection control.

White House officials stated that the disbanded panels were determined to be redundant, unnecessary, or ineffective. However, leaders in the scientific community warn that losing these committees strips federal agencies of vital real-world perspective and independent oversight. Russ Paulsen, chief executive of the advocacy group Research!America, emphasized that advisory boards offer a diversity of independent viewpoints that individual government organizations cannot replicate internally.

The panel cuts have halted collaborative efforts on pressing medical conditions. In early 2025, federal officials appointed a specialized advisory committee to address long COVID, bringing together patient advocates like Boston STEM educator Netia McCray and clinical experts like Dr. Alexandra Yonts of Children's National Hospital in Washington, D.C. The administration dissolved the committee before it could convene its first meeting, delaying interdisciplinary work on treatments for the debilitating condition affecting millions of Americans.

Public health experts express similar concerns regarding infectious disease management. The administration also terminated the Healthcare Infection Control Practices Advisory Committee, which advised the Centers for Disease Control and Prevention. Infectious disease specialists, including Dr. Hilary Babcock and Yale physician Dr. Scott Roberts, noted that the absence of federal advisory guidance complicates efforts to manage rising threats like the drug-resistant fungus Candida auris. Roberts warned that losing national advisory oversight creates a patchwork of treatment protocols across hospitals, potentially accelerating the spread of dangerous pathogens.

Researchers and former federal officials caution that the loss of advisory panels creates long-term structural gaps in U.S. science policy. Without regular input from practicing clinicians, academic researchers, and industry specialists, federal agencies risk siloing critical information and struggling to translate scientific literature into actionable public health policies.

#TrumpAdministration #SciencePolicy #PublicHealth #LongCOVID #CDC #Healthcare #UnitedStates #NetiaMcCray